BoonMarket.com: BoonMarket.com Launches Coverage of HepaLife Technologies, Inc.

SANTA BARBARA, CA, Nov 09, 2007 (M2 PRESSWIRE via COMTEX) -- HPLF | charts | news | PowerRating -- BoonMarket.com announced today their renewed interest in HepaLife Technologies, Inc. (OTCBB: HPLF). HPLF has been mentioned on BoonMarket.com in the past and recent developments within the company have compelled BoonMarket.com to closely follow the company once again.

Don't be crazy enough to ignore the riveting insight we provide. In-depth analysis of this and other companies can be viewed through BoonMarket.com's special email alerts. You can sign up for these alerts for free (limited time only) by visiting http://visitor.constantcontact.com/email.jsp?m=1101186369563

----------------------------------------------------

HPLF news from 11/08/07:

HepaLife(TM) Announces Exclusive License Agreement with U.S. Government Agency for Liver Cell Lines

HepaLife Technologies, Inc. today announced that the Company has entered into an exclusive license agreement with the U.S. Department of Agriculture, Agricultural Research Service (USDA, ARS) for the use of patented liver cell lines in artificial liver devices and in-vitro toxicological testing platforms.

The terms of the agreement cover specific patents and the PICM-19 hepatocyte cell lines. Financial details were not disclosed.

----------------------------------------------------

About BoonMarket.com

BoonMarket.com has become the premier stop for those investors who wish to experience huge profits via up-and-coming publicly traded companies. For more information, please see our contact information below.

----------------------------------------------------

About HepaLife Technologies, Inc.

HepaLife Technologies, Inc. is a biotechnology company focused on the identification and development of cell-based technologies and products. Current cell-based technologies under development by HepaLife include 1) the first-of-its-kind artificial liver device, 2) proprietary in-vitro toxicology and pre-clinical drug testing platforms, and 3) novel cell-culture based vaccine production to protect against the spread of influenza viruses among humans, including potentially the high pathogenicity H5N1 virus. For additional information, please visit www.hepalife.com.

----------------------------------------------------

Disclaimer: Never invest in any stock featured on the BoonMarket.com website or email alerts unless you can afford to lose your entire investment. Please read our full disclaimer at: http://www.boonmarket.com/legaldisclaimer.html. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements set forth in this press release constitute ''forward-looking statements.'' Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the word expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance.

CONTACT: BoonMarket.com Tel: +1 805 426 9292 e-mail: profiles@boonmarket.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index